Innovative Medicines Canada
Innovative Medicines Canada represents Canada’s innovative pharmaceutical industry. We help our members discover, develop, and deliver innovative medicines and vaccines. Our membership consists of more than 50 companies, from established organizations to fledgling startups, all of whom are revolutionizing healthcare through the discovery and development of new medicines and vaccines. Guided by a strict Code of Ethical Practices, we work with governments, insurance companies, healthcare professionals and stakeholders to advance the field and enhance the wellbeing of Canadians. We are committed to being valued partners in Canada’s healthcare system. We aim to achieve these goals by forming effective alliances and supporting policies, improving Canada’s regulatory environment, widen access to innovative medicines and protect intellectual property. We believe in ensuring that Canadians have access to the innovative treatments they need and that our activities are a fundamental part of safeguarding our healthcare system for future generations. Our work allows our members to focus on what matters: delivering better healthcare solutions to Canadians.
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi entities in Canada employ approximately 1,900 people. In 2017 we invested over $123 million in R&D in Canada, creating jobs, business and opportunity throughout the country. Sanofi, Empowering Life.
Alexion Pharma Canada
Alexion is focused on providing innovative treatments to patients with severe and life-threatening rare diseases for which there are few, if any, effective treatment options. In 2009, Alexion began operations in Canada to serve patients locally. We aim to work in partnership with all stakeholders including healthcare providers, patient advocacy organizations and government in order to best serve patients. By expanding the knowledge and awareness of rare diseases, we help the medical community improve the process for diagnosis and treatment. Our goal is to bring hope to patients and families by delivering life-changing therapies.
In Canada, Soliris® has received marketing authorization from Health Canada for all patients with PNH. Soliris® is also approved by Health Canada as safe and effective for use in children and adults with atypical HUS to inhibit complement-mediated thrombotic microangiopathy (TMA). To further advance the understanding of PNH and atypical HUS in the Canadian population, Alexion Canada sponsors disease registries that enroll treated and untreated patients who are diagnosed with these conditions. This is our commitment to ongoing research into the rare conditions that our therapies treat.
Learn more about Alexion’s research and development efforts.
Horizon Therapeutics Canada
Horizon Therapeutics Canada is a wholly owned subsidiary of Horizon Pharma plc, a biopharmaceutical company focused on improving patients’ lives by developing and commercializing differentiated and accessible medicines that address unmet medical needs in the fields of rare diseases, rheumatology and primary care. Founded in 2008 as a small start-up, Horizon has evolved in less than a decade into a global biopharmaceutical company active in several important therapeutic fields.
Taiho Pharma Canada Inc.
Taiho Pharma Canada, Inc., a Canadian subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), is located in Oakville, Ontario and managed by Taiho Oncology based in Princeton, New Jersey. Taiho Pharma’s mission in Canada is to lead oncology innovation, drive research and transform the lives of Canadians living with cancer. Taiho Oncology has established world class clinical development and commercial organizations that work urgently to develop and market innovative cancer treatments. Taiho Oncology Inc. has an oral oncology pipeline consisting of both novel anti-metabolic agents and selectively targeted agents. Advanced technology, dedicated researchers, and state of the art facilities are helping Taiho define the way the world treats cancer. It’s our work; it’s our passion; it’s our legacy.
AdMare BioInnovation is a global life sciences venture powering the industry by creating and growing companies of scale- while training the scientific and business talent needed to drive them to become leading global anchors here in Canada.
We build collaborations with the very best partners from academia, industry, patient foundations, the investment community, and other Key Opinion Leaders to provide the specialized expertise and infrastructure to identify, validate and advance promising discoveries, and transform them into commercially viable investment opportunities for the private sector – and ultimately into new therapies for patients.
BDO Canada has spent more than 90 years providing assurance, accounting, tax, and advisory services to a broad range of clients across the country. And as a member firm of the international BDO network, we leverage access to resources and advisors in more than 150 countries around the world.
Founded in 1921, we have grown from a single office in Winnipeg to more than 3,000 partners and professionals in over 100 offices across Canada. Yet our strengths remain firmly rooted in the communities we serve.
At BDO, we aim to create a collaborative working environment that makes it possible for our professionals and clients to achieve their goals. We always begin at the local, individual level, delivering highly personalized guidance, industry-specific knowledge, and unparalleled service to exceed the expectations of every client – public or private, big or small. And as our team and our clients’ needs expand globally, we draw on our resources around the world.
Ernst & Young LLP
At EY, we are committed to building a better working world — with increased trust and confidence in business, sustainable growth, development of talent in all its forms, and greater collaboration. We want to build a better working world through our own actions and by engaging with like-minded organizations and individuals. This is our purpose — and why we exist as an organization. Running through our organization is a strong sense of obligation to serve a number of different stakeholders who count on us to deliver quality and excellence in everything we do. We want to use our global reach and scale to convene the conversation about the challenges facing economies and the capital markets. When business works better, the world works better. Learn more about our commitment to building a better working world.